Emergent Biosolutions Inc Stock Prediction and Forecast [EBS]

AI-generated source summary

The analysis for Emergent Biosolutions Inc (EBS) on January 15, 2026, indicates a negative outlook, with the stock ranked as a 'Sell Candidate' and its status downgraded. Technically, the stock has broken a strong rising short-term trend, suggesting a potential shift. Resistance is identified at $11.15. The 3-month trend suggests a 28.25% change, while the 12-month analysis projects a 57.96% change. On the last trading day, the stock closed at $10.95, dropping 12.68% with a 14.47% fluctuation. Volume increased alongside falling prices, indicating increased risk. Key news includes a $100 million loan prepayment, a $21.5 million BioThrax delivery order, and FDA approval for a new manufacturing site. However, a lawsuit against a former CEO for alleged insider trading creates legal and reputational risks. Analyst ratings are mixed. General ratings show 'Strong Sell' for cash flow and dividend earnings, but 'Buy' for return on equity/asset and price-to-book ratios. The P/E ratio is neutral at 7.68. Technical signals are predominantly negative, with sell signals from MACD, Pivots, Short MA, and Long MA. Support levels are at $10.81, with further support at $9.48 and $9.06. Insider trading data shows positive insider power. Despite some positive trends, the overall evaluation is negative, expecting weak performance in the coming days or weeks. The stock is considered undervalued at $10.95, with an anticipated opening on January 16th at $11.46.

AI-generated summary based on the source content.

Evidence and evaluation progress

1. Original source published

   16 Jan 2026, 04:29 UTC

   The analyst published the original source item.

2. Source recorded by Tahlil Plus

   18 May 2026, 20:23 UTC

   The public source was preserved as the evidence record for this case.

3. Market predictions extracted

   18 May 2026, 20:48 UTC

   1 eligible signal linked to this case.

4. Outcome tracking started

   02 Jul 2026, 02:11 UTC

   Tahlil Plus began monitoring the extracted predictions.

5. First prediction resolved

   02 Jul 2026, 02:11 UTC

   The first evaluable outcome in this case reached a terminal result.

6. Case evaluation completed

   02 Jul 2026, 02:11 UTC

   All evaluable predictions in this case reached terminal outcomes.